Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Opat

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
Advances in Therapy|July 28, 2022
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three StudiesWei Xu, Shenmiao Yang, Constantine S Tam, et al.
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Journal of Hematology & Oncology|October 15, 2021
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trialsKeshu Zhou, Dehui Zou, Jianfeng Zhou, et al.
Cancer Medicine|September 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysisYuqin Song, Keshu Zhou, Dehui Zou, et al.
Ejhaem|April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry projectBriony Shaw, Eliza Chung, Cameron Wellard, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
Occupational and Environmental Medicine|September 18, 2023
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control studyMichael K Odutola, Marina T van Leeuwen, Fiona J Bruinsma, et al.
Blood|June 13, 2012
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesisKamil Wolyniec, Jake Shortt, Elisa de Stanchina, et al.
Haematologica|March 7, 2024
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance studyAllison Barraclough, Shivam Agrawal, Dipti Talaulikar, et al.
European Journal of Haematology|December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryJames Nguyen, Cameron Wellard, Eliza Chung, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
Advances in Therapy|July 28, 2022
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three StudiesWei Xu, Shenmiao Yang, Constantine S Tam, et al.
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Journal of Hematology & Oncology|October 15, 2021
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trialsKeshu Zhou, Dehui Zou, Jianfeng Zhou, et al.
Cancer Medicine|September 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysisYuqin Song, Keshu Zhou, Dehui Zou, et al.
Ejhaem|April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry projectBriony Shaw, Eliza Chung, Cameron Wellard, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
Occupational and Environmental Medicine|September 18, 2023
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control studyMichael K Odutola, Marina T van Leeuwen, Fiona J Bruinsma, et al.
Blood|June 13, 2012
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesisKamil Wolyniec, Jake Shortt, Elisa de Stanchina, et al.
Haematologica|March 7, 2024
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance studyAllison Barraclough, Shivam Agrawal, Dipti Talaulikar, et al.
European Journal of Haematology|December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryJames Nguyen, Cameron Wellard, Eliza Chung, et al.
Pageof 13